Wandercraft’s innovative AI-driven exoskeleton is paving the way for wheelchair users to walk again, offering new hope and independence. The technology, inspired by personal stories including that of spinal stroke survivor Caroline Laubach, is transforming mobility for millions. The exoskeleton, developed by Nicolas Simon and his team after seeing their family members struggle with mobility due to Charcot-Marie-Tooth disease, has already proven effective in rehabilitation clinics and is now entering clinical trials for daily use. The device, cleared by the FDA and approved in Europe, has enabled patients to take over a million steps per month as part of their recovery, marking a significant advancement in assistive technology.
Wandercraft’s AI-driven exoskeleton is revolutionizing mobility for wheelchair users, offering a new way to regain independence and walk again. The technology, inspired by real-life experiences, is transforming the lives of millions. Caroline Laubach, a spinal stroke survivor and full-time wheelchair user, has been a key test pilot for the exoskeleton, demonstrating its life-changing potential. Her experience highlights the profound impact this device can have on daily life.
For Laubach, using the exoskeleton is more than just a technological breakthrough; it’s about reclaiming a sense of freedom and connection. ‘When I’m in the exoskeleton, I feel more free than I do in my daily life,’ she said. ‘It gives me the opportunity to walk around and talk to people at eye level.’ These personal stories underscore the emotional and practical benefits of the technology, showing how it can help users feel more visible, connected, and empowered in their communities.
Wandercraft’s mission is to create advanced mobility solutions that help people move through the world with greater independence. Co-founder Nicolas Simon, who founded the company in 2012 after seeing his family members struggle with mobility due to Charcot-Marie-Tooth disease, has been instrumental in the development of the exoskeleton. Alongside Matthieu Masselin and Jean-Louis Constanza, who also had personal connections to the cause, Simon’s vision has driven the creation of this groundbreaking technology.
The company’s first exoskeleton, the Atalante X, has already made a significant impact in over 100 clinics and research centers worldwide. Approved by the FDA and recognized in Europe, the device has enabled patients to take over a million steps each month as part of their rehabilitation. This has already helped hundreds regain mobility and independence, marking a major milestone in assistive technology.
Wandercraft is now taking the next step with the development of the Personal Exoskeleton prototype, which is currently in clinical trials in New York and New Jersey. This new model is designed for daily life, allowing users to move at home, work, and in the community. The exoskeleton uses NVIDIA AI to adapt instantly to each user’s movements, providing smooth and stable walking on various surfaces. Users can control the device with a joystick, making it accessible to people with a wide range of abilities.
The collaboration with Nvidia is a critical part of Wandercraft’s progress. The team uses Nvidia Isaac Sim, a powerful simulation tool, to test and refine the exoskeleton in virtual environments before real-world trials. They are also exploring Nvidia’s healthcare robotics and edge computing platforms to make the device smarter and more responsive. This partnership aims to bring more advanced and intuitive mobility solutions to users across the globe.
Wandercraft has also launched Walk in New York, a state-of-the-art physical therapy practice and Atalante X walk center located at 345 Park Avenue South. This initiative represents a partnership between Wandercraft and licensed physical therapy professionals, offering personalized screenings, hands-free walking sessions, and comprehensive neurorehabilitation services. The center’s focus on personalized care and innovation makes it a welcoming space for anyone interested in rediscovering mobility, whether for themselves or a loved one.
The company’s continued commitment to improving lives extends beyond just the technology. They are actively working toward FDA approval for the Personal Exoskeleton, with plans to make it available to millions of wheelchair users in the U.S. and beyond. They are also seeking participants for their clinical trials, with plans for Medicare coverage in the future. The ultimate goal is to provide a more accessible and effective mobility solution that can be used in everyday settings, enabling users to live independently and confidently.
Wandercraft’s journey reflects a larger trend in technology and healthcare, where AI and robotics are being used to improve the quality of life for individuals with disabilities. This innovation has the potential to reshape our understanding of mobility, independence, and the possibilities for those who have faced significant physical challenges. The exoskeleton’s impact extends beyond just the technical achievements; it represents a shift in how we approach disability and the potential for technology to empower individuals in new and meaningful ways.